Nanjing Luye Pharmaceutical Co., Ltd.

Nanjing Luye Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Hong Kong listed company Luye Pharma Group, with a registered capital of 116717 million RMB and about 600 employees. The company focuses on the R&D, production and sales of new high-end anti-tumor drugs and high-end pharmaceutical excipients, insists on the enterprise mission of "professional technology serving human health", and has developed into the earliest and largest national key high-tech enterprise in research, production and sales of liposome drugs in China. The company's leading products are Tiandixin (lentinan for injection), Lipitor (paclitaxel liposome for injection), Tiandida (Amifostine for injection), etc.
 

The company established a research and development center in 1996 with a total investment of more than 50 million yuan and a construction area of 4000 square meters. The R & D center has advanced facilities and complete supporting facilities. It has built a complete liposome drug preparation technology platform and formed a perfect drug research and development engineering technical conditions. The company participated in the establishment of the State Key Laboratory of long-acting and targeted preparations, led the construction of Jiangsu liposome drug Engineering Technology Research Center, Jiangsu liposome drug Engineering Center and other four new drug preparation research and development platforms at provincial level, owned Nanjing Pharmaceutical Excipient engineering technology research center and Nanjing Pharmaceutical Excipient Engineering Research Center, two new pharmaceutical excipient research and development platforms at municipal level, it also has a national post-doctoral research station and a graduate student station in Jiangsu Province. It has been recognized as the key enterprise R&D institution, innovation demonstration enterprise and excellent enterprise in Jiangsu Province.